Market Overview

Siemens Healthineers Transforms Care Delivery with Innovative New Tests for Diagnosing Heart Attacks Faster

Share:
  • The Siemens Healthineers High-Sensitivity Troponin I assays can
    detect lower levels of troponin compared to conventional assays.
  • Troponin indicates damage to the heart muscle, and greater
    precision measures slight, yet critical, changes so physicians can
    properly triage patients sooner.
  • The TnIH assays that enable fast results and earlier diagnosis for
    heart attack patients are now available in the U.S.

Siemens Healthineers announced today it is helping to shorten the time
doctors can diagnose a life-threatening heart attack with the
introduction of two assays that offer unparalleled precision. U.S. Food
and Drug Administration cleared High-Sensitivity Troponin I assays (TnIH)1
for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic
analyzers from Siemens Healthineers to aid in the early diagnosis of
myocardial infarctions—commonly known as heart attacks. When a patient
experiencing chest pain enters the emergency department, a physician
orders a blood test to determine whether troponin is present. As blood
flow to the heart is blocked, the heart muscle begins to die in as few
as 30 to 60 minutes and releases troponin into the bloodstream.

The high-sensitivity performance of the two new Siemens Healthineers
TnIH assays offers the ability to detect lower levels of troponin at
significantly improved precision at the 99th percentile, and detect
smaller changes in a patient's troponin level as repeat testing occurs.
This design affords clinicians greater confidence in the results with
precision that provides the ability to measure slight, yet critical,
changes to begin treatment.2,3 As science progresses,
guidelines for determining high-sensitivity also evolves. These TnIH
assays meet the latest industry guidelines.

Chest pain is the cause of more than eight million visits annually
nationwide to emergency departments, but only 5.5 percent of those
visits lead to serious diagnoses such as heart attacks.4
Armed with data to properly triage patients sooner or to exclude
myocardial infarctions, the Siemens Healthineers TnIH assays can help
support testing initiatives tied to improving patient experience.

"Our emergency department is overcrowded with patients. If we can do a
more efficient job at triaging patients to receive the proper level of
care and to discharge the patients who do not need to stay in the
emergency department, this will have a tremendous economic advantage for
our healthcare system," said Dr. Alan Wu, Chief of Clinical Chemistry
and Toxicology at Zuckerberg San Francisco General Hospital and Trauma
Center.

Learn more about High-Sensitivity
Troponin I from Siemens Healthineers
in booth #2812 during the
70th AACC Annual Scientific Meeting & Clinical Lab Expo taking place
from July 31 to August 2 in Chicago, Ill.

1 Product availability may vary from country to country and
is subject to varying regulatory requirements.
2 Eggers
K, Jernberg T, Ljung L, Lindahl B. High-Sensitivity Cardiac
Troponin-Based Strategies for the Assessment of Chest Pain Patients—A
Review of Validation and Clinical Implementation Studies. Clin Chem.
2018;64(7). DOI: 10.1373/clinchem.2018.287342
3
Collinson P. High-sensitivity troponin measurements: challenges and
opportunities for the laboratory and the clinician. Annals of
Clinical Biochemistry.
2016;53(2) 191–195. DOI:
10.1177/0004563215619946
4 Hsia RY, Hale Z, Tabas JA. A
National Study of the Prevalence of Life-Threatening Diagnoses in
Patients With Chest Pain. JAMA Intern Med. 2016;176(7):1029–1032.
DOI:10.1001/jamainternmed.2016.2498

Siemens Healthineers enables healthcare providers worldwide to
increase value by empowering them on their journey towards expanding
precision medicine, transforming care delivery, improving patient
experience and digitalizing healthcare. A leader in medical technology,
Siemens Healthineers is constantly innovating its portfolio of products
and services in its core areas of diagnostic and therapeutic imaging and
in laboratory diagnostics and molecular medicine. Siemens Healthineers
is also actively developing its digital health services and enterprise
services. In fiscal 2017, which ended on September 30, 2017, Siemens
Healthineers generated revenue of €13.8 billion and profit of €2.5
billion and has about 48,000 employees worldwide. Further information is
available at www.siemens-healthineers.com.

View Comments and Join the Discussion!